Clinical Now with Featured Trials from the 2009 ASCO Annual Meeting!

Besides a price drop to $9.99, the latest version (1.4) of the Clinical Trials iPhone app brings a new feature to the Bookmarks page: a section called Featured Trials.

In this section we'll be highlighting the major trials in oncology coming out of the ASCO 2009 Annual Meeting. This will make it easier for our users to reference the details of these trials while they're in Orlando, or off-site from anywhere in the world where they have a connection.

So far we have Featured Trials that coincide with ASCO abstracts being presented on:

  • Abstract 1017. IV trastuzumab-Mcc-DM1 for HER2-positive metastatic breast cancer (NCT00679211)
  • Abstract P3. Standard chemotherapy with or without BSI-201 for triple negative breast cancer (NCT00540358)
  • Abstract CRA501. PARP inhibitor for advanced breast cancer ( NCT00494234)
  • Abstract CRA4027. STEPP: Skin toxicity treatment for patients with metastatic colorectal cancer (NCT00332163)
  • Abstract 8006. First-line IRESSA vs carboplatin/paclitaxel in stage IIIB/IV non-small cell lung cancer (NCT00322452)
  • Abstract CRA8003. ZODIAC: Vandetanib and docetaxel for locally advanced or metastatic non-small cell lung cancer (NCT00312377)
  • Abstract 4503. Gemcitabine with or without cisplatin for metastatic cholangiocarcinoma or other biliary tract tumors (NCT00262769)
  • Abstract 1005. RIBBON-1: Bevacizumab and chemotherapy in untreated metastatic breast cancer (NCT00262067)
  • Abstract LBA8002. ATLAS: Bevacizumab with or without erlotinib for first-line treatment of NSCLC (NCT00257608)
  • Abstract CRA5507. Gemcitabine/cisplatin/radiation and adjuvant gemcitabine/cisplatin vs cisplatin/radiation and no adjuvant therapy for cervical cancer (NCT00191100)
  • Abstract CRA8000. Pemetrexed and best supportive care vs best supportive care alone in non-small cell lung cancer (NCT00102804)
  • Abstract LBA4. Fluorouracil, leucovorin and oxaliplatin with or withour bevacizumab in patients with stage II or III colon cancer (NCT00096278)
  • Abstract 2. Tumor-derived idiotype vaccine (BiovaxID) for follicular lymphoma (NCT00091676)
  • Abstract LBA4505. ESPAC-3(v2): Adjuvant gemcitabine vs fluorouracil and leucovorin for patients with resected pancreatic cancer (NCT00058201)
  • Abstract 9511. Ginger for chemotherapy-related nausea (NCT00040742)
  • Abstract 10067. Antibody-based immunotherapy for high-risk neuroblastoma (NCT00026312)
  • Abstract LBA4009. ACT II: Radiation plus fluorouracil with or without chemotherapy for primary anal cancer (NCT00025090)
  • Abstract CRA9011. Aldeslukin with or without vaccine therapy for locally advanced metastatic melanoma (NCT00019682)
  • Abstract CRA7502. MSH2 and adjuvant cisplatin-based chemotherapy after curative resection of NSCLC (NCT00002823)
  • Abstract P1. Early chemotherapy based on CA125 levels in ovarian cancer (NCT00002895)

Be sure to check your Featured Trials listing as we add more to the page and keep up with ASCO 2009!

Download Clinical from the App Store, or see our featured ASCO trials demo video below (flash required).